With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening its scope beyond rare diseases. The new and improved  8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare Disorders Summit, will unite senior leaders from the likes of Pfizer, REGENXBIO, Vertex, Vivet Therapeutics, Carbon Biosciences, Beam Therapeutics, and the FDA to tackle the field’s biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand.

Take this unique opportunity to gain full visibility of cutting-edge developments from translation through to commercialization, gaining full competitor insight to benchmark novel approaches and inform and fast-track your gene therapy through the clinic and expand your patient reach.